A Phase II Prospective Multi-institutional Trial of Adjuvant Active Specific Immunotherapy Following Curative Resection of Colorectal Cancer Hepatic Metastases: Cancer ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2008-01

AUTHORS

Mitchell C. Posner, Donna Niedzwiecki, Alan P. Venook, Donna R. Hollis, Hedy L. Kindler, Edward W. Martin, Richard L. Schilsky, Richard M. Goldberg, for the Cancer and Leukemia Group B

ABSTRACT

BACKGROUND: Patients with curatively resected colorectal cancer hepatic metastases often harbor occult metastatic disease and are at high risk of experiencing recurrence. This patient cohort is ideally suited to test novel therapies such as immunotherapy. We treated patients-post-hepatic resection-with anti-idiotype monoclonal antibody vaccines to the tumor-associated antigens carcinoembryonic antigen (CeaVac) and human milk fat globule (TriAb), both of which are co-expressed in more than 90% of colorectal cancer patients. METHODS: Vaccinations commenced 6-12 weeks post-hepatic resection and consisted of four biweekly treatments of 2 mg CeaVac and TriAb, then monthly treatments for 2 years, then on every other month for 3 years. The primary endpoint was to investigate the proportion of patients recurrence-free at 2 years, and the objective of the study was to demonstrate that at least 58% would be recurrence-free at this time to consider the regimen worthy of further study. RESULTS: Between July 2001 and October 2004, 56 patients were accrued; 52 patients with margin-negative resection were eligible for analysis. Hepatic lobectomy was performed in 56% of patients with a median of one metastasis (range 1-3). Of the 52 eligible patients, 49 were evaluable for the primary end point. Median follow-up was 3.1 years. The proportion of patients recurrence-free at 2 years was 39%, with a lower confidence bound (LCB) of 0.29. Median recurrence-free survival was 16 months. The 2-year overall survival was 94% (95% CI, 0.81, 0.98). Only 10% of patients had documented grade-3 adverse events. CONCLUSIONS: Anti-idiotype monoclonal antibody vaccine therapy with CeaVac and TriAb as an adjuvant to curative resection of colorectal cancer hepatic metastases is well tolerated but did not improve 2-year recurrence-free survival when compared with the expected value of 40% reported for hepatic resection alone. More... »

PAGES

158-164

Identifiers

URI

http://scigraph.springernature.com/pub.10.1245/s10434-007-9654-7

DOI

http://dx.doi.org/10.1245/s10434-007-9654-7

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1002296347

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/18008108


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Anti-Idiotypic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cancer Vaccines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoembryonic Antigen", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Chemotherapy, Adjuvant", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Colorectal Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glycolipids", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glycoproteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hepatectomy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunity, Cellular", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunotherapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Liver Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Rate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vaccination", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "name": [
            "University of Chicago, 5841 S Maryland Avenue (MC5031), 60637, Chicago, IL"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Posner", 
        "givenName": "Mitchell C.", 
        "id": "sg:person.0662666376.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0662666376.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Duke University Hospital", 
          "id": "https://www.grid.ac/institutes/grid.189509.c", 
          "name": [
            "CALGB Statistical Center, Duke University Medical Center, Durham, NC"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Niedzwiecki", 
        "givenName": "Donna", 
        "id": "sg:person.0761643572.59", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0761643572.59"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of California, San Francisco", 
          "id": "https://www.grid.ac/institutes/grid.266102.1", 
          "name": [
            "University of California at San Francisco, San Francisco, CA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Venook", 
        "givenName": "Alan P.", 
        "id": "sg:person.01347652015.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01347652015.55"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Duke University Hospital", 
          "id": "https://www.grid.ac/institutes/grid.189509.c", 
          "name": [
            "CALGB Statistical Center, Duke University Medical Center, Durham, NC"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hollis", 
        "givenName": "Donna R.", 
        "id": "sg:person.01065623247.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01065623247.40"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "University of Chicago, 5841 S Maryland Avenue (MC5031), 60637, Chicago, IL"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kindler", 
        "givenName": "Hedy L.", 
        "id": "sg:person.01072156003.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01072156003.42"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The Ohio State University Wexner Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.412332.5", 
          "name": [
            "The Ohio State University Medical Center, Columbus, OH"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Martin", 
        "givenName": "Edward W.", 
        "id": "sg:person.01165001257.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01165001257.49"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "University of Chicago, 5841 S Maryland Avenue (MC5031), 60637, Chicago, IL"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schilsky", 
        "givenName": "Richard L.", 
        "id": "sg:person.01133375256.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01133375256.39"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of North Carolina at Chapel Hill", 
          "id": "https://www.grid.ac/institutes/grid.10698.36", 
          "name": [
            "University of North Carolina at Chapel Hill, Chapel Hill, NC"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Goldberg", 
        "givenName": "Richard M.", 
        "id": "sg:person.016472106717.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016472106717.33"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "for the Cancer and Leukemia Group B", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s11605-006-0061-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002763338", 
          "https://doi.org/10.1007/s11605-006-0061-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.soc.2007.04.014", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004059415"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3322/canjclin.57.1.43", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005586480"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2006.06.8353", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012458227"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa032691", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014051315"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1245/s10434-006-9068-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034768212", 
          "https://doi.org/10.1245/s10434-006-9068-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/bjs.1800771115", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041536693"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3816/cbc.2003.s.005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041969488"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(98)07186-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042406890"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/bjs.1800840719", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049625308"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1080/01621459.1958.10501452", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1058299418"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1999.17.9.2889", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074549924"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2000.18.1.148", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074572225"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1076895666", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1080143750", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1080152639", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1997.15.3.938", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083057206"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1998.16.5.1788", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083260955"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1083347281", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2008-01", 
    "datePublishedReg": "2008-01-01", 
    "description": "BACKGROUND: Patients with curatively resected colorectal cancer hepatic metastases often harbor occult metastatic disease and are at high risk of experiencing recurrence. This patient cohort is ideally suited to test novel therapies such as immunotherapy. We treated patients-post-hepatic resection-with anti-idiotype monoclonal antibody vaccines to the tumor-associated antigens carcinoembryonic antigen (CeaVac) and human milk fat globule (TriAb), both of which are co-expressed in more than 90% of colorectal cancer patients.\nMETHODS: Vaccinations commenced 6-12 weeks post-hepatic resection and consisted of four biweekly treatments of 2 mg CeaVac and TriAb, then monthly treatments for 2 years, then on every other month for 3 years. The primary endpoint was to investigate the proportion of patients recurrence-free at 2 years, and the objective of the study was to demonstrate that at least 58% would be recurrence-free at this time to consider the regimen worthy of further study.\nRESULTS: Between July 2001 and October 2004, 56 patients were accrued; 52 patients with margin-negative resection were eligible for analysis. Hepatic lobectomy was performed in 56% of patients with a median of one metastasis (range 1-3). Of the 52 eligible patients, 49 were evaluable for the primary end point. Median follow-up was 3.1 years. The proportion of patients recurrence-free at 2 years was 39%, with a lower confidence bound (LCB) of 0.29. Median recurrence-free survival was 16 months. The 2-year overall survival was 94% (95% CI, 0.81, 0.98). Only 10% of patients had documented grade-3 adverse events.\nCONCLUSIONS: Anti-idiotype monoclonal antibody vaccine therapy with CeaVac and TriAb as an adjuvant to curative resection of colorectal cancer hepatic metastases is well tolerated but did not improve 2-year recurrence-free survival when compared with the expected value of 40% reported for hepatic resection alone.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1245/s10434-007-9654-7", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2693576", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2693667", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2693361", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2693524", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2693353", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2693347", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2693620", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1105545", 
        "issn": [
          "1068-9265", 
          "1534-4681"
        ], 
        "name": "Annals of Surgical Oncology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "15"
      }
    ], 
    "name": "A Phase II Prospective Multi-institutional Trial of Adjuvant Active Specific Immunotherapy Following Curative Resection of Colorectal Cancer Hepatic Metastases: Cancer and Leukemia Group B Study 89903", 
    "pagination": "158-164", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "0aeeedd4273d35796c2abeacd8a3230ede298d0eed9d47c882ebe1c4ed6d4b54"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "18008108"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "9420840"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1245/s10434-007-9654-7"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1002296347"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1245/s10434-007-9654-7", 
      "https://app.dimensions.ai/details/publication/pub.1002296347"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T13:12", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8659_00000498.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1245/s10434-007-9654-7"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1245/s10434-007-9654-7'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1245/s10434-007-9654-7'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1245/s10434-007-9654-7'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1245/s10434-007-9654-7'


 

This table displays all metadata directly associated to this object as RDF triples.

298 TRIPLES      21 PREDICATES      71 URIs      44 LITERALS      32 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1245/s10434-007-9654-7 schema:about N0d8863c61a664c1c992ced015aa4bd7d
2 N182b89728d7e4beba8c24eb8f6297db7
3 N2c889e59baa04e1a9388fd40840df761
4 N2d9b52e268fa44d0b3a8efae732b63d2
5 N39024f6275da464cbedd22332d419344
6 N468c0e00a5304280b76cb2cba2a07835
7 N50ba4b4dd2f5430886a9d3d6689eddba
8 N58493948c11f4d36835b0601d5e0a40b
9 N634067f233ff4eb1ba74ef8b8e08d37d
10 N6509e4ef22f1437e936218c45d978c1a
11 N76fe298540f14808b9b7e9993dd971e7
12 N96683b054dd24dd199948e16aa54be51
13 N967f51ec8ec243ae9ed2daa0d58927ac
14 N97f254b2a2b2409eb7bf9af7cd11fe32
15 N9ddf1b7c04c74ba587c94234e364926c
16 Na0499dd331394a17b3f73bb5270f0752
17 Nad7e10bbb06f4571910d40b430496786
18 Naf9a8c4cbe874fc9b6f873d676b8f87c
19 Nb4eb9f1ad6064c59a8f109f4641cd2fd
20 Nb8725b8d336d4b9cb21cf543040b9793
21 Nddbb9c89d6d54f0baff16f730777bd55
22 Nec19338b8187412985c5cba5d384d069
23 Nf74e4073204a4d4fa413534b2d6f44e3
24 anzsrc-for:11
25 anzsrc-for:1112
26 schema:author Na07bc6d393624e519045ba2080f10e72
27 schema:citation sg:pub.10.1007/s11605-006-0061-3
28 sg:pub.10.1245/s10434-006-9068-y
29 https://app.dimensions.ai/details/publication/pub.1076895666
30 https://app.dimensions.ai/details/publication/pub.1080143750
31 https://app.dimensions.ai/details/publication/pub.1080152639
32 https://app.dimensions.ai/details/publication/pub.1083347281
33 https://doi.org/10.1002/bjs.1800771115
34 https://doi.org/10.1002/bjs.1800840719
35 https://doi.org/10.1016/j.soc.2007.04.014
36 https://doi.org/10.1016/s0140-6736(98)07186-4
37 https://doi.org/10.1056/nejmoa032691
38 https://doi.org/10.1080/01621459.1958.10501452
39 https://doi.org/10.1200/jco.1997.15.3.938
40 https://doi.org/10.1200/jco.1998.16.5.1788
41 https://doi.org/10.1200/jco.1999.17.9.2889
42 https://doi.org/10.1200/jco.2000.18.1.148
43 https://doi.org/10.1200/jco.2006.06.8353
44 https://doi.org/10.3322/canjclin.57.1.43
45 https://doi.org/10.3816/cbc.2003.s.005
46 schema:datePublished 2008-01
47 schema:datePublishedReg 2008-01-01
48 schema:description BACKGROUND: Patients with curatively resected colorectal cancer hepatic metastases often harbor occult metastatic disease and are at high risk of experiencing recurrence. This patient cohort is ideally suited to test novel therapies such as immunotherapy. We treated patients-post-hepatic resection-with anti-idiotype monoclonal antibody vaccines to the tumor-associated antigens carcinoembryonic antigen (CeaVac) and human milk fat globule (TriAb), both of which are co-expressed in more than 90% of colorectal cancer patients. METHODS: Vaccinations commenced 6-12 weeks post-hepatic resection and consisted of four biweekly treatments of 2 mg CeaVac and TriAb, then monthly treatments for 2 years, then on every other month for 3 years. The primary endpoint was to investigate the proportion of patients recurrence-free at 2 years, and the objective of the study was to demonstrate that at least 58% would be recurrence-free at this time to consider the regimen worthy of further study. RESULTS: Between July 2001 and October 2004, 56 patients were accrued; 52 patients with margin-negative resection were eligible for analysis. Hepatic lobectomy was performed in 56% of patients with a median of one metastasis (range 1-3). Of the 52 eligible patients, 49 were evaluable for the primary end point. Median follow-up was 3.1 years. The proportion of patients recurrence-free at 2 years was 39%, with a lower confidence bound (LCB) of 0.29. Median recurrence-free survival was 16 months. The 2-year overall survival was 94% (95% CI, 0.81, 0.98). Only 10% of patients had documented grade-3 adverse events. CONCLUSIONS: Anti-idiotype monoclonal antibody vaccine therapy with CeaVac and TriAb as an adjuvant to curative resection of colorectal cancer hepatic metastases is well tolerated but did not improve 2-year recurrence-free survival when compared with the expected value of 40% reported for hepatic resection alone.
49 schema:genre research_article
50 schema:inLanguage en
51 schema:isAccessibleForFree false
52 schema:isPartOf N0aaa68ba18f44fdc92aaa4b9c9759990
53 Nbd3df0c3873c437fb9df0b9529f16265
54 sg:journal.1105545
55 schema:name A Phase II Prospective Multi-institutional Trial of Adjuvant Active Specific Immunotherapy Following Curative Resection of Colorectal Cancer Hepatic Metastases: Cancer and Leukemia Group B Study 89903
56 schema:pagination 158-164
57 schema:productId N3280654570064db9b866eaed8ebd1dd3
58 N8ff509074c2a40cfb23f3ce69650a71c
59 N941dbc9b86094d779b1c1b6571611657
60 N942987466c9344edaa84da6d3e9f9d44
61 Nfa4cf21e09dc4235b1eefef849a48c5c
62 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002296347
63 https://doi.org/10.1245/s10434-007-9654-7
64 schema:sdDatePublished 2019-04-10T13:12
65 schema:sdLicense https://scigraph.springernature.com/explorer/license/
66 schema:sdPublisher N51cce231c5764ec8b40ee83297686d93
67 schema:url http://link.springer.com/10.1245/s10434-007-9654-7
68 sgo:license sg:explorer/license/
69 sgo:sdDataset articles
70 rdf:type schema:ScholarlyArticle
71 N0aaa68ba18f44fdc92aaa4b9c9759990 schema:volumeNumber 15
72 rdf:type schema:PublicationVolume
73 N0d8863c61a664c1c992ced015aa4bd7d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
74 schema:name Immunotherapy
75 rdf:type schema:DefinedTerm
76 N182b89728d7e4beba8c24eb8f6297db7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
77 schema:name Liver Neoplasms
78 rdf:type schema:DefinedTerm
79 N24b4b953311c4de3bf557156e7739110 rdf:first sg:person.016472106717.33
80 rdf:rest Ne375a19758e247419dc659b4907cac00
81 N29a4ee39bd6f44c3b0bf731a68173480 rdf:first sg:person.01165001257.49
82 rdf:rest N7b6bf3e49d18499dbf6793c30a10c626
83 N2c889e59baa04e1a9388fd40840df761 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
84 schema:name Carcinoembryonic Antigen
85 rdf:type schema:DefinedTerm
86 N2d9b52e268fa44d0b3a8efae732b63d2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
87 schema:name Chemotherapy, Adjuvant
88 rdf:type schema:DefinedTerm
89 N3005962c9ce04f8ea16e6317ed657642 rdf:first sg:person.01347652015.55
90 rdf:rest N58ac095e6d394116ab4955aca1b9eef4
91 N3280654570064db9b866eaed8ebd1dd3 schema:name doi
92 schema:value 10.1245/s10434-007-9654-7
93 rdf:type schema:PropertyValue
94 N39024f6275da464cbedd22332d419344 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
95 schema:name Colorectal Neoplasms
96 rdf:type schema:DefinedTerm
97 N468c0e00a5304280b76cb2cba2a07835 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
98 schema:name Aged, 80 and over
99 rdf:type schema:DefinedTerm
100 N503e620a4ee64afc9bb9771ef657f896 schema:name University of Chicago, 5841 S Maryland Avenue (MC5031), 60637, Chicago, IL
101 rdf:type schema:Organization
102 N50ba4b4dd2f5430886a9d3d6689eddba schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Male
104 rdf:type schema:DefinedTerm
105 N51cce231c5764ec8b40ee83297686d93 schema:name Springer Nature - SN SciGraph project
106 rdf:type schema:Organization
107 N53813f5f3bfa465285074282cced0ca5 schema:name University of Chicago, 5841 S Maryland Avenue (MC5031), 60637, Chicago, IL
108 rdf:type schema:Organization
109 N58493948c11f4d36835b0601d5e0a40b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Vaccination
111 rdf:type schema:DefinedTerm
112 N58ac095e6d394116ab4955aca1b9eef4 rdf:first sg:person.01065623247.40
113 rdf:rest N69ed058b5f2047479d503dfe46659d73
114 N634067f233ff4eb1ba74ef8b8e08d37d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Female
116 rdf:type schema:DefinedTerm
117 N6509e4ef22f1437e936218c45d978c1a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Hepatectomy
119 rdf:type schema:DefinedTerm
120 N69ed058b5f2047479d503dfe46659d73 rdf:first sg:person.01072156003.42
121 rdf:rest N29a4ee39bd6f44c3b0bf731a68173480
122 N76fe298540f14808b9b7e9993dd971e7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Middle Aged
124 rdf:type schema:DefinedTerm
125 N7b6bf3e49d18499dbf6793c30a10c626 rdf:first sg:person.01133375256.39
126 rdf:rest N24b4b953311c4de3bf557156e7739110
127 N8ff509074c2a40cfb23f3ce69650a71c schema:name nlm_unique_id
128 schema:value 9420840
129 rdf:type schema:PropertyValue
130 N941dbc9b86094d779b1c1b6571611657 schema:name readcube_id
131 schema:value 0aeeedd4273d35796c2abeacd8a3230ede298d0eed9d47c882ebe1c4ed6d4b54
132 rdf:type schema:PropertyValue
133 N942987466c9344edaa84da6d3e9f9d44 schema:name pubmed_id
134 schema:value 18008108
135 rdf:type schema:PropertyValue
136 N96683b054dd24dd199948e16aa54be51 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Treatment Outcome
138 rdf:type schema:DefinedTerm
139 N967f51ec8ec243ae9ed2daa0d58927ac schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Humans
141 rdf:type schema:DefinedTerm
142 N97f254b2a2b2409eb7bf9af7cd11fe32 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Glycoproteins
144 rdf:type schema:DefinedTerm
145 N97f547b0f1704ffaa2044490672aca20 rdf:first sg:person.0761643572.59
146 rdf:rest N3005962c9ce04f8ea16e6317ed657642
147 N9ddf1b7c04c74ba587c94234e364926c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Antibodies, Anti-Idiotypic
149 rdf:type schema:DefinedTerm
150 Na0499dd331394a17b3f73bb5270f0752 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Adult
152 rdf:type schema:DefinedTerm
153 Na07bc6d393624e519045ba2080f10e72 rdf:first sg:person.0662666376.33
154 rdf:rest N97f547b0f1704ffaa2044490672aca20
155 Nad7e10bbb06f4571910d40b430496786 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Immunity, Cellular
157 rdf:type schema:DefinedTerm
158 Naf9a8c4cbe874fc9b6f873d676b8f87c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Cancer Vaccines
160 rdf:type schema:DefinedTerm
161 Nb4eb9f1ad6064c59a8f109f4641cd2fd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Glycolipids
163 rdf:type schema:DefinedTerm
164 Nb8725b8d336d4b9cb21cf543040b9793 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Disease-Free Survival
166 rdf:type schema:DefinedTerm
167 Nbd3df0c3873c437fb9df0b9529f16265 schema:issueNumber 1
168 rdf:type schema:PublicationIssue
169 Nc0a431393b074399b5db84940cc42b74 schema:name University of Chicago, 5841 S Maryland Avenue (MC5031), 60637, Chicago, IL
170 rdf:type schema:Organization
171 Nddbb9c89d6d54f0baff16f730777bd55 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
172 schema:name Prospective Studies
173 rdf:type schema:DefinedTerm
174 Ne375a19758e247419dc659b4907cac00 rdf:first Nffc6f0b1261d4d3bbfafa0d26fafa035
175 rdf:rest rdf:nil
176 Nec19338b8187412985c5cba5d384d069 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Survival Rate
178 rdf:type schema:DefinedTerm
179 Nf74e4073204a4d4fa413534b2d6f44e3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name Aged
181 rdf:type schema:DefinedTerm
182 Nfa4cf21e09dc4235b1eefef849a48c5c schema:name dimensions_id
183 schema:value pub.1002296347
184 rdf:type schema:PropertyValue
185 Nffc6f0b1261d4d3bbfafa0d26fafa035 schema:familyName for the Cancer and Leukemia Group B
186 rdf:type schema:Person
187 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
188 schema:name Medical and Health Sciences
189 rdf:type schema:DefinedTerm
190 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
191 schema:name Oncology and Carcinogenesis
192 rdf:type schema:DefinedTerm
193 sg:grant.2693347 http://pending.schema.org/fundedItem sg:pub.10.1245/s10434-007-9654-7
194 rdf:type schema:MonetaryGrant
195 sg:grant.2693353 http://pending.schema.org/fundedItem sg:pub.10.1245/s10434-007-9654-7
196 rdf:type schema:MonetaryGrant
197 sg:grant.2693361 http://pending.schema.org/fundedItem sg:pub.10.1245/s10434-007-9654-7
198 rdf:type schema:MonetaryGrant
199 sg:grant.2693524 http://pending.schema.org/fundedItem sg:pub.10.1245/s10434-007-9654-7
200 rdf:type schema:MonetaryGrant
201 sg:grant.2693576 http://pending.schema.org/fundedItem sg:pub.10.1245/s10434-007-9654-7
202 rdf:type schema:MonetaryGrant
203 sg:grant.2693620 http://pending.schema.org/fundedItem sg:pub.10.1245/s10434-007-9654-7
204 rdf:type schema:MonetaryGrant
205 sg:grant.2693667 http://pending.schema.org/fundedItem sg:pub.10.1245/s10434-007-9654-7
206 rdf:type schema:MonetaryGrant
207 sg:journal.1105545 schema:issn 1068-9265
208 1534-4681
209 schema:name Annals of Surgical Oncology
210 rdf:type schema:Periodical
211 sg:person.01065623247.40 schema:affiliation https://www.grid.ac/institutes/grid.189509.c
212 schema:familyName Hollis
213 schema:givenName Donna R.
214 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01065623247.40
215 rdf:type schema:Person
216 sg:person.01072156003.42 schema:affiliation N503e620a4ee64afc9bb9771ef657f896
217 schema:familyName Kindler
218 schema:givenName Hedy L.
219 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01072156003.42
220 rdf:type schema:Person
221 sg:person.01133375256.39 schema:affiliation Nc0a431393b074399b5db84940cc42b74
222 schema:familyName Schilsky
223 schema:givenName Richard L.
224 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01133375256.39
225 rdf:type schema:Person
226 sg:person.01165001257.49 schema:affiliation https://www.grid.ac/institutes/grid.412332.5
227 schema:familyName Martin
228 schema:givenName Edward W.
229 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01165001257.49
230 rdf:type schema:Person
231 sg:person.01347652015.55 schema:affiliation https://www.grid.ac/institutes/grid.266102.1
232 schema:familyName Venook
233 schema:givenName Alan P.
234 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01347652015.55
235 rdf:type schema:Person
236 sg:person.016472106717.33 schema:affiliation https://www.grid.ac/institutes/grid.10698.36
237 schema:familyName Goldberg
238 schema:givenName Richard M.
239 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016472106717.33
240 rdf:type schema:Person
241 sg:person.0662666376.33 schema:affiliation N53813f5f3bfa465285074282cced0ca5
242 schema:familyName Posner
243 schema:givenName Mitchell C.
244 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0662666376.33
245 rdf:type schema:Person
246 sg:person.0761643572.59 schema:affiliation https://www.grid.ac/institutes/grid.189509.c
247 schema:familyName Niedzwiecki
248 schema:givenName Donna
249 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0761643572.59
250 rdf:type schema:Person
251 sg:pub.10.1007/s11605-006-0061-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002763338
252 https://doi.org/10.1007/s11605-006-0061-3
253 rdf:type schema:CreativeWork
254 sg:pub.10.1245/s10434-006-9068-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1034768212
255 https://doi.org/10.1245/s10434-006-9068-y
256 rdf:type schema:CreativeWork
257 https://app.dimensions.ai/details/publication/pub.1076895666 schema:CreativeWork
258 https://app.dimensions.ai/details/publication/pub.1080143750 schema:CreativeWork
259 https://app.dimensions.ai/details/publication/pub.1080152639 schema:CreativeWork
260 https://app.dimensions.ai/details/publication/pub.1083347281 schema:CreativeWork
261 https://doi.org/10.1002/bjs.1800771115 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041536693
262 rdf:type schema:CreativeWork
263 https://doi.org/10.1002/bjs.1800840719 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049625308
264 rdf:type schema:CreativeWork
265 https://doi.org/10.1016/j.soc.2007.04.014 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004059415
266 rdf:type schema:CreativeWork
267 https://doi.org/10.1016/s0140-6736(98)07186-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042406890
268 rdf:type schema:CreativeWork
269 https://doi.org/10.1056/nejmoa032691 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014051315
270 rdf:type schema:CreativeWork
271 https://doi.org/10.1080/01621459.1958.10501452 schema:sameAs https://app.dimensions.ai/details/publication/pub.1058299418
272 rdf:type schema:CreativeWork
273 https://doi.org/10.1200/jco.1997.15.3.938 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083057206
274 rdf:type schema:CreativeWork
275 https://doi.org/10.1200/jco.1998.16.5.1788 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083260955
276 rdf:type schema:CreativeWork
277 https://doi.org/10.1200/jco.1999.17.9.2889 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074549924
278 rdf:type schema:CreativeWork
279 https://doi.org/10.1200/jco.2000.18.1.148 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074572225
280 rdf:type schema:CreativeWork
281 https://doi.org/10.1200/jco.2006.06.8353 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012458227
282 rdf:type schema:CreativeWork
283 https://doi.org/10.3322/canjclin.57.1.43 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005586480
284 rdf:type schema:CreativeWork
285 https://doi.org/10.3816/cbc.2003.s.005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041969488
286 rdf:type schema:CreativeWork
287 https://www.grid.ac/institutes/grid.10698.36 schema:alternateName University of North Carolina at Chapel Hill
288 schema:name University of North Carolina at Chapel Hill, Chapel Hill, NC
289 rdf:type schema:Organization
290 https://www.grid.ac/institutes/grid.189509.c schema:alternateName Duke University Hospital
291 schema:name CALGB Statistical Center, Duke University Medical Center, Durham, NC
292 rdf:type schema:Organization
293 https://www.grid.ac/institutes/grid.266102.1 schema:alternateName University of California, San Francisco
294 schema:name University of California at San Francisco, San Francisco, CA
295 rdf:type schema:Organization
296 https://www.grid.ac/institutes/grid.412332.5 schema:alternateName The Ohio State University Wexner Medical Center
297 schema:name The Ohio State University Medical Center, Columbus, OH
298 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...